Sponsored Links
| Seattle Genetics Announces Discontinuation Of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm. Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|